- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00287872
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with thalidomide may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with thalidomide works in treating patients with newly diagnosed stage II or stage III multiple myeloma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
- Determine the antitumor efficacy of bortezomib and thalidomide in patients with newly diagnosed stage II or III multiple myeloma.
- Determine the incidence and severity of peripheral motor/sensory neuropathy in patients treated with this regimen.
- Assess the ability to mobilize and collect stem cells in patients who undergo future autologous peripheral stem cell transplantation.
- Determine the time to response in patients treated with this regimen.
- Assess the quality of life of patients treated with this regimen.
OUTLINE: This is an open-label study.
Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral thalidomide once daily on days 1-21. Treatment repeats every 21 days for at least 4 courses. Patients who plan to undergo transplantation AND achieve ≥ 50% reduction in the tumor burden proceed to transplantation off study. Patients who do not undergo transplantation receive 2 additional courses of therapy beyond best response for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Patients who achieve at least a partial response after completion of treatment may receive maintenance therapy comprising bortezomib IV every 2 months and oral thalidomide* once daily OR twice every 2 months (i.e., the day before and the day of bortezomib administration) in the absence of disease progression or unacceptable toxicity.
NOTE: *For patients who had previously discontinued thalidomide, maintenance therapy may consist of bortezomib only.
Quality of life is assessed at baseline, at the beginning of each study course, and after completion of study treatment.
After completion of study treatment, patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21231-2410
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Newly diagnosed Salmon-Durie stage II or III multiple myeloma
- Untreated disease OR patient underwent prior therapy for this cancer that lasted no more than 2 weeks
- Measurable paraprotein in serum or urine (serum free-lite assay measurement allowed)
- No evidence of cord compression requiring concurrent steroids
PATIENT CHARACTERISTICS:
- Creatinine clearance ≥ 30 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use 2 methods of contraception, including ≥ 1 highly effective method, 4 weeks before, during, and for ≥ 4 weeks after completion of study treatment
- No known HIV positivity
- No peripheral neuropathy ≥ grade 2
- No hypersensitivity to bortezomib, boron, or mannitol
PRIOR CONCURRENT THERAPY:
- No prior bortezomib
- More than 28 days since prior regimens with a duration of > 1 week but ≤ 2 weeks
- No steroids within 14 days prior to study entry
No concurrent corticosteroids except for the treatment of a nonmalignant condition
- May not exceed the equivalent dose of prednisone 10 mg/day
- No concurrent chemotherapy, immunotherapy, radiotherapy, or surgery
- No other concurrent investigational agents
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Bortezomib and Thalidomide
The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
|
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinical Response to Treatment
Prazo: 1-6 months
|
Clinical evaluations of disease response were determined with each cycle.
Bone marrow biopsies were done at baseline and at study termination.
Clinical responses were defined by the International Myeloma Working Group criteria: Stringent Complete Response (SCR), CR and normal free light chain ratio and no clonal cells in bone marrow; Complete Response (CR), Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; Very Good Partial Response (VGPR), Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; Partial Response (PR), ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours.
Objective response is defined as a best overall response of SCR, CR, VGPR, or PR.
|
1-6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)
Prazo: 1-6 months
|
Neuropathy was monitored using Total Neuropathy Score reduced (TNSr).
|
1-6 months
|
|
Mobilization of Stem Cells in Patients Proceeding to Autologous Peripheral Stem Transplantation
Prazo: 1-6 months
|
1-6 months
|
|
|
The Time to Response
Prazo: 1-6 months
|
1-6 months
|
|
|
Quality of Life
Prazo: 0-6 months
|
0-6 months
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Ivan Borrello, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças cardiovasculares
- Doenças Vasculares
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Neoplasias
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Doenças Hematológicas
- Distúrbios hemorrágicos
- Distúrbios hemostáticos
- Paraproteinemias
- Distúrbios das Proteínas Sanguíneas
- Mieloma múltiplo
- Neoplasias de Células Plasmáticas
- Efeitos Fisiológicos das Drogas
- Agentes Anti-Infecciosos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Inibidores de angiogênese
- Agentes Moduladores da Angiogênese
- Substâncias de crescimento
- Inibidores de crescimento
- Agentes antibacterianos
- Leprostáticos
- Talidomida
- Bortezomibe
Outros números de identificação do estudo
- J0456 CDR0000450772
- P30CA006973 (Concessão/Contrato do NIH dos EUA)
- JHOC-J0456
- JHOC-04063003
- MILLENNIUM-JHOC-J0456
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .